Ophthalmology

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.

At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.

One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.

New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.

An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.

Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.

Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.

Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.

The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.

Phase 2a results demonstrated the efficacy and safety of orally administered CU06-1004 and may warrant further clinical studies in DME.

SGLT2 inhibitors may provide a favorable impact on the risk of sight-threatening diabetic retinal complications compared with other glucose-lowering therapies.

We break down 5 top trials to keep an eye on at ASRS 2024, taking place in Stockholm, Sweden from July 17 to 20, 2024.

A case series analysis indicated that switching from aflibercept to faricimab could be a safe and effective option for patients with treatment-resistant nAMD.

Administrative claims database analysis revealed a lower AMD incidence in patients treated with JAK inhibitor therapy versus non–JAK-based immunotherapy.

Prior authorizations for the anti-VEGF therapies aflibercept, ranibizumab, and bevacizumab were almost always approved but delayed care for most patients.

Marking the end of a voluntary recall, the FDA approved updates to Susvimo regarding the ocular implant and refill needle.

Announced by Genentech on July 04, 2024, the prefilled, 6.0 mg syringe is designed to improve ease of administration and offer ophthalmologists with a ready-to-use version of the bispecific antibody.

Our June 2024 month-in-review includes the latest pipeline news, the impact of vision issues on public health, and expert-led insight on the latest in ophthalmology.

Across the Phase 2 ReCLAIM-2 trial, elamipretide demonstrated photoreceptor protection and the potential for visual function improvement in eyes with dry AMD.

Aflibercept-mrbb showed comparable safety, efficacy, pharmacokinetics, and immunogenicity compared with the reference product.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

Arshad Khanani, MD shares his excitement about the potential of elamipretide joining the treatment armamentarium in GA and his final thoughts on the topic.

Arshad Khanani, MD points to the viability of the mechanism of action of elamipretide for geographic atrophy in dry AMD, and what it could represent for patient outcomes.

Arshad Khanani, MD provides insight into the pivotal Phase 3 clinical trials investigating elamipretide for geographic atrophy in dry AMD.

Arshad Khanani, MD discusses the key findings on elamipretide from the Phase 2 ReCLAIM-2 clinical trial.

Arshad Khanani, MD describes the mechanism of action of elamipretide, an investigational product candidate for geographic atrophy in dry age-related macular degeneration.

Arshad Khanani, MD breaks down the current treatment options for geographic atrophy and provides insight into the therapeutic pipeline.

Revisits and new antibiotic dispensations were rare, regardless of initial topical antibiotic treatment, in children with acute infectious conjunctivitis.

Inconsistent estimates of self-reported impairment across surveys could impact surveillance on the size of the population with vision problems.